Dr. DiMartino joined Plexium in October 2024 as its chief medical officer and executive vice president of clinical and translational development.

Prior to joining Plexium, Dr. DiMartino provided strategic leadership and clinical translation support for multiple biotech companies to advance their programs from preclinical through early clinical development. Dr. DiMartino previously served as Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio, Inc. While at Kronos, he built a clinical and translational development group and led the development strategy and execution for three clinical stage programs. Prior to Kronos Bio, Dr. DiMartino was Vice President, Translational Development, Protein Homeostasis and Epigenetics Thematic Center of Excellence at Celgene Corp., with responsibilities for establishing and overseeing a team driving an industry leading epigenetic profiling capabilities in pursuit of chromatin modifier targets. Prior to Celgene, Dr DiMartino was Group Medical Director, BioOncology/ Exploratory Clinical Development at Genentech Inc., where he led the BCL2 (venetoclax, navitoclax) programs and managed a team advancing a broad portfolio of early-stage oncology compounds.

Dr. DiMartino received a B.A. in genetics from the University of California, Berkeley, a Ph.D. in immunology from Cornell University Graduate School of Medical Sciences, and an M.D. from the University of California, San Diego, School of Medicine. He completed a residency in pediatrics and a fellowship in pediatric hematology/oncology at the Lucile Salter Packard Children’s Hospital at Stanford, and a post-doctoral fellowship in the Department of Pathology at Stanford.